한글목차

세계의 바이오의약품 업계에 대해 조사분석했으며, 2020-2025년 중추신경계 공동 연구·라이선싱 계약 811건에 관한 계약 조건 등의 상세 데이터를 제공하고 있습니다.

목차

개요

제1장 서론

제2장 중추신경계 계약의 동향

• 서론
• 과거 수년간 중추신경계 파트너 계약
• 중추신경계 파트너 계약 : 계약 유형별
• 중추신경계 파트너 계약 : 산업 부문별
• 중추신경계 파트너 계약 : 개발 단계별
• 중추신경계 파트너 계약 : 기술 유형별
• 중추신경계 파트너 계약 : 적응증별

제3장 중추신경계 파트너 계약에 관한 재무적 계약 조건

• 서론
• 중추신경계 파트너 계약에 관한 공개된 재무 조건
• 중추신경계 파트너 계약 헤드라인 금액
• 중추신경계 계약 선불
• 중추신경계 계약 마일스톤 지불
• 중추신경계 로열티율

제4장 주요 중추신경계 계약과 교섭자

• 서론
• 중추신경계 파트너 계약 분야에서 가장 활발
• 중추신경계 분야에서 가장 활발한 교섭자 리스트
• 상위 중추신경계 계약(금액)

제5장 중추신경계 계약 문서 디렉토리

• 서론
• 계약서가 입수 가능한 중추신경계 파트너 계약

제6장 중추신경계 계약 : 치료 표적별

• 서론
• 계약 : 중추신경계 치료 표적별
• 계약 디렉토리
• 계약 디렉토리 - 중추신경계 계약 : 기업별(A-Z)(2020-2025년)
• 계약 디렉토리 - 중추신경계 계약 : 기술 유형별(2020-2025년)
• 계약 유형의 정의
• Biopharma Research Ltd 소개
• Current Partnering
• Current Agreements
• Current Partnering으로부터의 최근 리포트 타이틀

영문목차

Central Nervous System Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the central nervous system deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 811 central nervous system deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in central nervous system dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the central nervous system field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in central nervous system dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of central nervous system deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of central nervous system deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in central nervous system deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Central Nervous System Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse central nervous system collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Central Nervous System Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of central nervous system trends and structure of deals entered into by leading biopharma companies worldwide.

Central Nervous System Collaboration and Licensing Deals includes:

• Trends in central nervous system dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of central nervous system deal records covering pharmaceutical and biotechnology
• The leading central nervous system deals by value
• Most active central nervous system licensing dealmakers

In Central Nervous System Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Central Nervous System Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Central nervous system partnering by deal type
• 2.4. Central nervous system partnering by industry sector
• 2.5. Central nervous system partnering by stage of development
• 2.6. Central nervous system partnering by technology type
• 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for central nervous system partnering
• 3.3. Central nervous system partnering headline values
• 3.4. Central nervous system deal upfront payments
• 3.5. Central nervous system deal milestone payments
• 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in central nervous system partnering
• 4.3. List of most active dealmakers in central nervous system
• 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

• 5.1. Introduction
• 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by central nervous system therapeutic target
• Deal Directory
• Deal Directory - Central nervous system deals by company A-Z 2020 to 2025
• Deal Directory - Central nervous system deals by technology type 2020 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Central nervous system partnering since 2020
• Figure 2: Central nervous system partnering by deal type since 2020
• Figure 3: Central nervous system partnering by industry sector since 2020
• Figure 4: Central nervous system partnering by stage of development since 2020
• Figure 5: Central nervous system partnering by technology type since 2020
• Figure 6: Central nervous system partnering by indication since 2020
• Figure 7: Central nervous system deals with a headline value
• Figure 8: Central nervous system deals with upfront payment values
• Figure 9: Central nervous system deals with milestone payment
• Figure 10: Central nervous system deals with royalty rates
• Figure 11: Active central nervous system dealmaking activity since 2020
• Figure 12: Top central nervous system deals by value since 2020